Peptide Encyclopedia / HGH Fragment 176-191
EncyclopediaHGH Fragment 176-191 is a synthetic peptide matching the fat-mobilizing C-terminal region of human growth hormone, reported to trigger fat breakdown without the IGF-1 or blood-sugar effects of full-length GH. It is not FDA-approved and sells as a research chemical, with limited human data. Below you'll find reported dosing, reconstitution, safety, and legal status. Educational only, not medical advice.
| Category | GLP-1 / Metabolic |
| Regulatory status | Not FDA-approved as a finished drug. |
A synthetic peptide corresponding to the C-terminal region (amino acids 176-191) of human growth hormone, the portion associated with GH's lipolytic (fat-mobilizing) activity; it is reported to stimulate fat breakdown and oxidation without the IGF-1-raising or blood-glucose effects of full-length GH. Note: AOD-9604 is a closely related but distinct modified analog (adds an N-terminal tyrosine).
Short; reported on the order of minutes for the unmodified fragment, though precise human data are limited. It is a peptide.
Not FDA-approved as a finished drug. The closely related AOD-9604 received FDA self-affirmed GRAS status as a food ingredient in 2007 (which is not drug approval), and its obesity clinical program did not meet primary weight-loss endpoints. Currently sold as a research chemical.
Generally reported as well tolerated in short studies (injection-site reactions); long-term safety not established. Efficacy for human fat loss is not supported by positive pivotal trials.
Some human trials exist for AOD-9604 (did not meet primary endpoints); the unmodified fragment itself has limited human data. Largely animal/anecdotal for the marketed product.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. HGH Fragment 176-191 may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
